Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIGSeN
2022-501717-31-00Phase 3Authorised
- Sponsor
- Sørlandet sykehus
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of polyvalent human immunoglobulin in cryptogenic small fiber neuropathy (iSFN) and idiopathic sensory neuronopathy (ISN) (2 arms), sponsored by Sørlandet sykehus. Planned start Dec 2022; status: authorised.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
cryptogenic small fiber neuropathy (iSFN)idiopathic sensory neuronopathy (ISN)
Beyond the preview
Go deeper on 2022-501717-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501717-31-00.